The January 10, 2018, article by Fernandez et al, entitled "Outcome and Prognostic Factors in Stage III Favorable-Histology Wilms Tumor: A Report From the Children's Oncology Group Study AREN0532" (*J Clin Oncol* 10.1200/JCO.2017.73.7999), was published with errors.

The first two sentences on page 258 were given as:

We compared outcomes of the AREN0532 patients with outcomes of similar patients who received the same therapy in NWTS-5 (n = 780) by log-rank testing. The 4-year EFS in NWTS-5 was 84.4% (95% CI, 81.8% to 87.1%; P = .0597) and 4-year OS was 93.2% (95% CI, 91.3% to 95.1%; P = .0046).

It should have read as:

We compared outcomes of the AREN0532 patients with outcomes of similar patients **from the NWTS-5 studied and followed cohorts** who received the same therapy in NWTS-5 (n = **716**) by **the log-rank test**. The 4-year EFS in NWTS-5 was **86.5%** (95% CI, **83.8%** to **89.1%**; P = **.39**) and 4-year OS was **94.5%** (95% CI, **92.8%** to **96.3%**; P = **0.08**).

This has been corrected as of September 5, 2019. The authors apologize for the errors.

DOI: <https://doi.org/10.1200/JCO.19.02265>